How appropriate use criteria was created for PSMA-PET imaging
“There is a rather extensive process of how to develop appropriate use criteria. It is primarily based on literature and evidence, systematic reviews, and analysis of those data,” says Hossein Jadvar, MD, PhD.
In this video, Hossein Jadvar, MD, PhD, discusses the process for creating the appropriate use criteria for prostate-specific membrane antigen (PSMA) PET imaging that was recently released in the Journal of Nuclear Medicine. Jadvar is a professor of urology and radiology in the Keck School of Medicine at the University of Southern California in Los Angeles.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Studies show low urinary bladder interference on flotufolastat F 18 scans
June 11th 2024“The ability to gather actionable information from PSMA PET scans is important for physicians to make informed decisions about patient management for men with prostate cancer,” says Eugene Teoh, MBBS, MRCP, FRCR, DPhil.
![[68Ga]Ga-PSMA-11 PET/CT shows value in initial staging of prostate cancer](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Furologytimes%2F6583419a0719128d5ec70eb6a2f5729faf857b50-1200x905.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "[68Ga]Ga-PSMA-11 PET/CT shows value in initial staging of prostate cancer")
